Historically, the clinical utility of PD-L1 expression assessment in melanoma has been regarded as controversial, considering the challenges associated with the interpretation of PD-L1 immunocolorations, the variability in the expression patterns of this biomarker and the role of other factors (such as tumor mutational burden, immune cell infiltration, and other immunological checkpoints) in immunotherapy response. Here, CD274 is linked to neoplasm.